<DOC>
	<DOCNO>NCT01710371</DOCNO>
	<brief_summary>To evaluate 18F-AV-133 image pancreas patient early type 2 diabetes , late type 2 diabetes , subject pre-diabetes healthy overweight/obese control subject . These subject also evaluate beta-cell function measure insulin C-peptide response challenge intravenous arginine basal glucose enhanced condition .</brief_summary>
	<brief_title>Quantitative 18F-AV-133 PET Imaging Subjects With Diabetes Healthy Controls</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male and/or female subject nonchildbearing potential age 30 65 year inclusive . Able tolerate PET , PET/CT MR image Estimated creatinine clearance &gt; = 60mL/min Informed consent document sign dated subject Subjects must willing able comply schedule visit , treatment laboratory test , scan study procedure . In addition , subject must meet classification requirement one follow 1 . Healthy Overweight 2 . Prediabetes 3 . T2DM ( T2DM ) Subjects chronic medical condition ( besides diabetes ) well control stable medication acceptable inclusion study . Subjects affiliated relative staff member either site Pfizer directly involve conduct trial . Conditions opinion study investigator may interfere subject 's ability participate study History allergic reaction drug/contrast agent history drug/alcohol abuse Subjects receive investigational medication within last 30 day radiopharmaceutical past 7 day . Pregnant nursing female ; female childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>